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Abstract 
Enantioselective capillary electrophoretic methods were elaborated for the 
determination of the enantiomeric purity of (R)-MDL 100,907 and its preparatively resolved 
key intermediate compound during the synthesis route. The pKa values of the intermediate 
compound and the end product determined by CE were 10.5 ± 0.1 and 9.0 ± 0.1, respectively. 
The enantiopurity of the intermediate compound can be monitored in fully protonated state by 
applying 15 mM sulfobuthylether-β-cyclodextrin at pH 5 when the peak belonging to the 
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impurity migrates before the main component. The fact that the consecutive steps of the 
synthesis do not affect the enantiomeric purity was verified by the other, newly developed CE 
method. The enantiomers of rac-MDL 100,907 were resolved by 15 mM carboxymethyl--
cyclodextrin at pH 3. The applicability (selectivity, LOD, LOQ, repeatability, precision and 
accuracy) of the methods was studied as well. 
 
1. Introduction 
MDL 100,907 (Volinanserin; (2,3-dimethoxyphenyl)({1-[2-(4-
fluorophenyl)ethyl]piperidin-4-yl})methanol) is a highly selective and potent 5-HT2A receptor 
antagonist [1].  Its R-enantiomer binds to its receptor with higher affinity (Ki~ 0.4 nM) than 
its racemic form (Ki~ 2.1 nM) [2].  MDL 100,907 has about 100-fold or greater selectivity for 
5-HT2A than for the other 5-HT receptor subtypes [3-4]. This drug is widely used in the 
investigation of the 5-HT2A receptor function [1, 5-8]. The [
11
C] MDL 100,907, the 
radioactive derivative is applied in positron emission tomography (PET) for receptor mapping 
and determination of drug-induced receptor occupancy in pathological conditions (e.g. in 
schizophreny) [2-6]. 
The synthesis route (Scheme 1) described by Herth [2] was chosen from the available 
methods [2, 9-10] to prepare (R)-MDL 100,907 for R&D purposes with an 3% enantiomer 
impurity as maximum. The preparative chiral resolution of the key intermediate (compound 7: 
(2,3-dimethoxyphenyl)(piperidin-4-yl)methanol) by the isolation of the diastereomeric salt 
pairs of the enantiomers of compound 7 prepared with (+)-di-O,O’-p-toluyl-D-tartaric acid is 
an important step. This step is followed by an N-alkylation procedure resulting in the (R)-
MDL 100,907, the end product (compound 10). The efficiency of the preparative optical 
resolution of compound 7 can be verified either by NMR [10] or by HPLC [2]. For this 
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indirect NMR method the sample (compound 8) goes through a diastereomeric salt derivation 
with (R)-1,1’-binaphthyl-2,2’-diyl hydrogen phosphate.  
The aim of our study is to develop an easier, direct stereoselective method which 
consumes less time, solvents and samples. Therefore, novel capillary electrophoretic (CE) 
methods for the determination of enantiomeric purity of the key intermediate (compound 8) 
and the end product (compound 10) were elaborated.  
[Scheme 1] 
 
2. Materials and Methods 
2.1. Materials 
 Anhydrous (+)-di-O,O’-p-toluyl-D-tartaric acid  were purchased from Sigma-Aldrich 
(Steinheim, Germany) and all other reagents and solvents, which were used for the synthesis, 
were supplied by commercial vendors. Background electrolyte (BGE) buffer components 
phosphoric acid, sodium hydroxide, glacial acetic acid and ethanol were purchased from 
Merck GmbH (Darmstadt, Germany).  Heptakis (2, 3, 6-tri-O-methyl)-β-cyclodextrin 
(TRIMEB), randomly methylated β-cyclodextrin (RAMEB; Degree of substitution (DS) =12), 
carboxymethyl-β-cyclodextrin (CMBCD; DS=3.5), carboxymethyl--cyclodextrin (CMGCD; 
DS=3), sulfobuthylether-β-cyclodextrin (SBEBCD; DS=4) and sulfobuthylether--
cyclodextrin (SBEGCD; DS=4) are the products of CycloLab Ltd. (Budapest, Hungary).  
 
2.2. Capillary electrophoresis 
  Capillary electrophoresis was performed with an Agilent Capillary Electrophoresis 
3D
CE system (Agilent Technologies, Waldbronn, Germany) applying bare fused silica 
capillary of 64.5 cm total and 56 cm effective length with 50 μm I.D. (Agilent Technologies, 
Santa Clara, CA, USA). On-line UV absorption at 200 nm was monitored by DAD UV-Vis 
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detector. The capillary was thermostated at 25°C. Between measurements, the capillary was 
rinsed subsequently with 0.1 M HCl, 1.0 M NaOH, 0.1 M NaOH and distilled water for 3 
minutes each and with BGE for 5 minutes. The applied BGEs were 82 mM boric acid (pH 9), 
65 mM acetic acid (pH 5), 255 mM acetic acid (pH 4) and 50 mM phosphoric acid (pH 3) and 
pHs were adjusted by sodium hydroxide. Compounds 7, 8 and 10 (cf. Scheme 1) and  rac-
MDL 100,907 were dissolved in ethanol (1 mg/ml), and they were further diluted with 
distilled water. Samples were injected by 5×103 Pa pressure for 3 sec. Runs were performed 
in the positive-polarity mode with 30 kV. The resolution (Rs) of enantiomers is given by the 
following equation [11]: 
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where t is the migration time of the enantiomers (1, 2 in lower index), w(0.5) is the peak width 
at half height.  
 
2.3. Estimation of pKa values of the analytes 
  Experimental pKa values of the analytes were determined from the effective mobilities 
(μeff) measured at a pH where the analytes are in fully ionized state (pH 4) and at pH 9 where 
the analytes are mixtures of ionized and neutral states. pKa value of a mono-basic analyte can 
be calculated from equation 2 [12,13]. 
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where μeff is the effective mobility of the analyte, μeff,A+ is the effective mobilty of the mono-
basic analyte in fully ionized state. Predicted thermodynamical pKa values were calculated 
using the ChemAxon’s MarvinSketch and Marvin Calculator Plugin software (version 5.9.2) 
called as “Marvin” in the followings. 
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2.4. Determination of the stability constants of the complexes formed with CDs 
The apparent stability constants of complexes (K’) were determined at pH 3 and 5. 
The μeff was measured without chiral selector and at 5.0, 7.5, 10.0, 12.5, 15.0 mM 
concentrations of CMBCD, CMGCD, SBEBCD and SBEGCD. The measured mobilities 
were corrected by the relative viscosity (μ’eff= μeff×η/η0) of BGEs containing CDs [14-16] and 
were plotted against the applied molar concentration of CD derivatives ([CD]). Experimental 
points were fitted with non-linear curve fitting allowing non-limited successive iterations 
(Origin 8.6 software; goodness of fit: χ2<10-13 and R2>0.999) using equation 3 providing the 
apparent binding constant (K’) and the mobilities of the complexes (μcompl) [17-20]:  
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where μfree is the mobility of an analyte in BGE without selector. RSD values of the measured 
and calculated parameters were less than 10%. 
 
2.5. Evaluation of method applicability 
 The homogeneity of the peaks of the enantiomers of compound 7 and MDL 100,907 
was studied by injecting 0.1 mg/ml sample solutions of the raceme compounds. The 
identification of the peaks was carried out by spiking the raceme sample with the purified R-
enantiomers (compounds 8 and 10). Linearity of the methods for the separation of compound 
7 or MDL 100,907 was tested by raceme standards at 10, 20, 30, 40, 50, 60, 80, 100 µg/ml 
concentrations (i.e. 5, 10, 15, 20, 25, 30, 40, 50 µg/ml concentrations for the enantiomers 
respectively). Intra-day repeatability of the methods was studied by three repetitive injections 
of 5, 10 and 25 µg/ml concentrations of compounds 7 and rac-MDL 100,907, respectively. 
The inter-day repeatability was determined by repeating the above procedure at three 
consecutive days. Six-six samples with known concentrations of raceme solutions of 
compound 7 and MDL 100,907 (5 µg/ml and 10 µg/ml, respectively) were prepared and the 
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intra-day accuracies of the methods were established by the determination of the recoveries of 
the samples calculating their concentrations from the calibration. 
 
3. Results and Discussion 
 
3.1. Method development and optimization 
Experimental acidic dissociation constants (pKa) measured by CE were 10.5 ± 0.1 and 
9.0 ± 0.1 for compound 7 and for MDL 100,907, respectively. These data are in a good 
agreement with the predicted pKa values (10.05 and 8.75) calculated by “Marvin” software. 
Compound 7 and MDL 100,907 have basic character therefore their chiral separations 
were elaborated at pH 5 and pH 3 in their fully ionized state. According to the literature, the 
neutral or the anionic CD derivatives should be good choices for selectors when the analytes 
have cationic character [21]. Two neutral cyclodextrins – TRIMEB and RAMEB - and four 
acidic CDs - CMBCD, CMGCD, SBEBCD and SBEGCD - were chosen as potential selectors 
both for compound 7 and rac-MDL 100,907. The two neutral CD derivatives can not resolve 
our analytes. Since the migration times are high and the peak shapes show torsions in the 
presence of sulfobuthylether CD derivatives at pH 3 these results are not discussed here. 
Apparent stability constants (K’) and the mobilities (µcompl) of negatively charged CD 
complexes were determined (Table 1) as well. The acidic CD derivatives studied forms more 
stable complexes with the enantiomers of rac-MDL 100,907 than with the enantiomers of 
compound 7.  
[Table 1] 
Although the K’ values of the enantiomer pairs belonging to a given selector are 
slightly different these differences still resulted in the predicted migration orders of the 
enantiomers (EMO) in most but in one cases. Mainly the K’ of the S-enantiomers is higher 
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than that of the R-enantiomers giving ‘RS’ migration order. On the contrary, the reversed K’ 
ratio obtained for compound 7 in the presence of SBEBCD is concomitant with the ‘SR’ 
migration order. The corresponding µcompl-s differ from each other substantially only in the 
case of compound 7 using CMBCD at pH 3 presumably because this CD derivative contains a 
mixture of isomers [22]. The fact that here µcompl,R > µcompl,S could be the reason that the EMO 
is ‘RS’ despite that the EMO predicted from the difference in K’ should be the opposite of it, 
namely ‘SR’. The resolutions achieved and the corresponding EMOs are shown in Table 1. In 
CE good resolutions can be experienced for compound 7 by SBEBCD and SBEGCD at pH 5 
and by CMGCD at pH 5 and at pH 3 too. Despite the fact, that improved resolutions can be 
obtained by CMGCD or SBEGCD as well, SBEBCD results in a more favorable EMO since 
the impurity migrates before the main component (Fig. 1) in contrast to the reversed EMO 
obtained by CMGCD or SBEGCD (Table 1). Appropriate separation for the enantiomers of 
the rac-MDL 100,907 can be achieved only by CMGCD at pH 3 (Fig. 1). However, the 
contaminant S-enantiomer migrates slower than the R-enantiomer. It is worth mentioning that 
CMGCD is only partially ionized at pH 3 because its pKa value is approximately 3.75.  
[Fig. 1] 
 
The concentrations of the CD derivatives were also optimized according to the 
measured K’ and µcompl values. Selectivities slightly increase with increasing concentrations of 
the selectors in the 5-15 mM concentration range in both cases. According to our experience 
15 mM of the selectors provide appropriate resolutions (cf. Fig. 1). Whereas higher 
concentrations of the selectors may improve selectivity but at the same time undesirable Joule 
heating and peak torsions can occur. Furthermore, in the presence of higher concentrations of 
SBEBCD compound 7 co-migrates with EOF and therefore the enantiomer ratio of the 
analyte can not be evaluated.   
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The achiral CE methods in the absence of CD selectors at pH 5 and at pH 3 are 
suitable (Rs = 8.12,  = 1.07 and Rs = 13.36,  = 1.16, respectively) for determining the 
amount of the remaining compound 7 impurity in MDL 100,907 sample.  
 
3.2. Method application 
Applicability of both proposed methods was checked as well [Table 2] according to 
the recommendations of the Good Laboratory Practice [23]. The values of the intra-day and 
inter-day repeatability of the S-enantiomers were less than 10% being below the acceptable 
maximum value for this technique. Consequently both methods have good precision. The 
enantiomer impurities in compound 8 and in the end product, compound 10 were determined 
as well. The ratios of the contaminant enantiomers are a little bit high but these values are 
acceptable in the case of a product synthesized for R&D purposes. The preparative optical 
resolution step of the synthesis needs to be improved if the drug is produced for medical 
purposes. The enantiomer excess did not increase substantially during the synthesis steps 
carried out after the optical resolution of the intermediate compound. It means that this last 
part of synthesis route does not involve steps resulting in racemization.  
 
[Table 2] 
 
4. Conclusions 
A chiral CE method was developed using SBEBCD at pH 5 for the evaluation of the 
enantiopurity of the intermediate compound 8 purified by stereoselective resolution during the 
synthesis route of (R)-MDL 100,907. We determined by the other method elaborated here 
(applying CMGCD at pH 3) that the consecutive steps of the synthesis could not spoil the 
enantiomer purity of the end product. This latter method and the method at pH 5 without 
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selector are equally appropriate to verify the amount of the contaminant intermediate 
compounds.  
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Scheme 1: Synthesis route of (R)-MDL 100,907 [2] 
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Table 1: Resolution (Rs) and migration order of the enantiomers (EMO) using 15 mM selector, stability constants (K’) and effective mobilities 
(µcompl) of the complexes of enantiomers of MDL 100,907 and compound 7 using different CD derivatives at pH 3 and pH 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Rs using 15 mM SBEGCD 
sample CD pH 
 
Rs 
 
 
EMO 
 
 
K' (M-1) 
 
 
μcompl  (10
-5 cm2/Vs) 
 
   15 mM CD  
 
S 
 
 
R 
 
 
S 
 
 
R 
 
     average SD average SD average SD average SD 
compound 7 CMBCD 3 0.92 R,S 19.0 2.6 25.1 2.5 -1.02 2.47 4.13 1.32 
MDL 100,907 CMBCD 3 0.18 R,S 109.4 1.4 110.2 2.0 -3.06 0.12 -2.96 0.17 
compound 7 CMGCD 3 3.14 R,S 31.1 3.6 28.0 3.0 2.51 1.68 3.12 1.50 
MDL 100,907 CMGCD 3 1.84 R,S 44.4 1.6 42.0 1.7 -1.63 0.44 -1.66 0.51 
compound 7 CMBCD 5 0.45 R,S 75.7 0.9 74.3 0.8 -3.61 0.15 -3.48 0.15 
MDL 100,907 CMBCD 5 0  447.5 3.5 447.5 3.5 -14.68 0.05 -14.68 0.05 
compound 7 CMGCD 5 3.48 R,S 101.4 2.5 87.4 2.5 -6.69 0.32 -6.08 0.39 
MDL 100,907 CMGCD 5 0.80 R,S 150.7 3.9 140.4 6.2 -9.69 0.27 -10.05 0.50 
compound 7 SBEBCD 5 1.80 S,R 103.0 1.7 106.7 1.2 -5.91 0.20 -6.47 0.14 
MDL 100,907 SBEBCD 5 0  428.7 3.1 428.7 3.1 -17.58 0.05 -17.58 0.05 
compound 7 SBEGCD 5 1.80 R,S 87.3 0.7 85.0 1.4 -3.89 0.11 -3.21 0.20 
MDL 100,907 SBEGCD 5 0.3* R,S 169.6 20.8 161.9 19.7 -8.45 1.14 -8.81 1.18 
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Fig. 1: Stereoselective separation of enantiomers of compound 7 (using 15 mM SBEBCD at pH 5) (a), compound 8 (b); insert (c) represents a 
region of electropherogram “b” magnified by 50 times. Separation of the enantiomers of rac-MDL 100,907 (using 15 mM CMGCD at pH 3) (d), 
compound 10 (e); insert (f) represents a region of electropherogram “e” magnified by 50 times. 
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Table 2: Applicability of the two methods developed for the stereoselective analysis of rac-
MDL 100,907 and of compound 7 
 
Analytes compound 7 MDL 100,907  
Conditions 15 mM  SBEBCD; pH 5 15 mM CMGCD; pH 3 
Enantiomer migration order S,R R,S 
LOD (S/N=3) 1.25 µg/ml 2.5 µg/ml 
LOQ (S/N=10) 5.0 µg/ml 5.0 µg/ml 
Linearity   
concentration range 5-50 µg/ml 5-50 µg/ml 
 linear equation y = 0.0625x + 0.8207 y = 0.1336x + 0.0077 
coefficient of determination r
2
 = 0.999 r
2
 = 0.999 
Precision   
intra-day reproducibility   
RSD (migration time) 0.9 % (1.2; 0.7; 0.9%) 0.9 % (1.0; 0.9; 0.7%) 
RSD (area) 5.0 % (7.5; 7.1;0.4%) 2.5 % (3.4; 1.6; 2.5%) 
RSD (resolution) 0.6 % (0.9; 0.6; 0.4%) 2.7 % (1.5; 5.0; 1.4%) 
inter-day reproducibility   
RSD (migration time) 2.3 % (3.3; 1.6; 2.1%) 0.9 % (1.0; 0.7; 1.1%) 
RSD (area) 5.7 % (10; 6.2; 0.9%) 3.4 % (5.6; 2.2; 2.4%) 
RSD (resolution) 1.0 % (0.5; 1.4; 1.2%) 2.4 % (3.0; 2.5; 1.8%) 
Accuracy   
recovery 
93.7 %, 99.5 %, 93.7%, 
96.6 %, 93.7 %, 96.6% 
97.2 %, 98.7 %, 96.6 %, 
97.2 %, 97.2 %, 96.1% 
RSD 2.3 % 0.8 % 
Bulk   
impurity content 1.3 ±0.8% 2.0± 0.8% 
 
Values refer to the contaminant S-enantiomers 
y = peak area corrected with migration time, x= concentration of the analytes in μg/ml.  
Precision data are presented the average reproducibility values calculated from the individual 
RSD values in the brackets referring to the 5, 10, 25 µg/ml S-enantiomer samples, respectively. 
Recovery data were determined at 5 µg/ml and 10 µg/ml concentrations of compound 7 and 
MDL 100,907, respectively. 
